130655-91-3

Upstream product

• 101973-76-6 2-acetylthiomethyl-4-(4-bromophenyl)-4-oxobutanoic acid 
• 130655-89-9 5-(4-bromo-phenyl)-2,3-dihydro-thiophene-3-carboxylic acid methyl ester 

Downstream Products

• 194142-05-7 [5-(4-bromo-phenyl)-thiophen-3-yl]-methanol 
• 130656-06-3 5-(4-bromo-phenyl)-thiophene-3-carboxylic acid 
• 194142-07-9 2-[5-(4-bromo-phenyl)-thiophen-3-ylmethyl]-malonic acid diethyl ester 
• 194142-08-0 3-[5-(4-bromo-phenyl)-thiophen-3-yl]-propionic acid ethyl ester 
• 194142-09-1 3-[5-(4-bromo-phenyl)-thiophen-3-yl]-propionic acid 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)-thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate (5h), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds.